Goldman Sachs analyst David Roman lowered the firm’s price target on Kestra Medical (KMTS) to $23 from $24 and keeps a Neutral rating on the shares. The company’s Q3 results were in line with preliminary estimates, driven by 51% y/y growth in ASSURE wearable cardiac defibrillators prescriptions and improving revenue conversion, the analyst tells investors in a research note. The implied Q4 guidance is also setting a reasonable bar, as the mid-point implies a sequential $600k step-up in revenue, against a backdrop of strong Rx trends, the firm added.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical Technologies Reports Strong Q3 Growth
- Closing Bell Movers: Allegro MicroSystems down 13% as On Semi pulls out
- Kestra Medical reports Q3 EPS ($1.25) vs. ($1.18) last year
- Kestra Medical sees FY25 revenue $58M-$58.5M, consensus $58.24M
- Kestra Medical Technologies Ltd.: Positioned for Growth with Strong Financials and Innovative Market Strategy